Meeting
2015 Genitourinary Cancers Symposium
Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer.
Authors
Esther K. Lee
Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Esther K. Lee , Rehana Jamani , Scott R. Berry , Carlo DeAngelis , Angie Giotis , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 261)
DOI
10.1200/jco.2015.33.7_suppl.261
Abstract #
261
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem.
First Author: Rehana Jamani
Poster
2017 ASCO Quality Care Symposium
Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.
First Author: Dominic Pilon
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
First Author: Daniel J. George